Cargando…
Nano/microparticle Formulations for Universal Influenza Vaccines
Influenza affects millions of people worldwide and can result in severe sickness and even death. The best method of prevention is vaccination; however, the seasonal influenza vaccine often suffers from low efficacy and requires yearly vaccination due to changes in strain and viral mutations. More co...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741137/ https://www.ncbi.nlm.nih.gov/pubmed/34997352 http://dx.doi.org/10.1208/s12248-021-00676-9 |
_version_ | 1784629423017820160 |
---|---|
author | Hendy, Dylan A. Amouzougan, Eva A. Young, Isabella C. Bachelder, Eric M. Ainslie, Kristy M. |
author_facet | Hendy, Dylan A. Amouzougan, Eva A. Young, Isabella C. Bachelder, Eric M. Ainslie, Kristy M. |
author_sort | Hendy, Dylan A. |
collection | PubMed |
description | Influenza affects millions of people worldwide and can result in severe sickness and even death. The best method of prevention is vaccination; however, the seasonal influenza vaccine often suffers from low efficacy and requires yearly vaccination due to changes in strain and viral mutations. More conserved universal influenza antigens like M2 ectodomain (M2e) and the stalk region of hemagglutinin (HA stalk) have been used clinically but often suffer from low antigenicity. To increase antigenicity, universal antigens have been formulated using nano/microparticles as vaccine carriers against influenza. Utilizing polymers, liposomes, metal, and protein-based particles, indicators of immunity and protection in mouse, pig, ferrets, and chicken models of influenza have been shown. In this review, seasonal and universal influenza vaccine formulations comprised of these materials including their physiochemical properties, fabrication, characterization, and biologic responses in vivo are highlighted. The review is concluded with future perspectives for nano/microparticles as carrier systems and other considerations within the universal influenza vaccine delivery landscape. [Figure: see text] |
format | Online Article Text |
id | pubmed-8741137 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-87411372022-01-10 Nano/microparticle Formulations for Universal Influenza Vaccines Hendy, Dylan A. Amouzougan, Eva A. Young, Isabella C. Bachelder, Eric M. Ainslie, Kristy M. AAPS J Review Article Influenza affects millions of people worldwide and can result in severe sickness and even death. The best method of prevention is vaccination; however, the seasonal influenza vaccine often suffers from low efficacy and requires yearly vaccination due to changes in strain and viral mutations. More conserved universal influenza antigens like M2 ectodomain (M2e) and the stalk region of hemagglutinin (HA stalk) have been used clinically but often suffer from low antigenicity. To increase antigenicity, universal antigens have been formulated using nano/microparticles as vaccine carriers against influenza. Utilizing polymers, liposomes, metal, and protein-based particles, indicators of immunity and protection in mouse, pig, ferrets, and chicken models of influenza have been shown. In this review, seasonal and universal influenza vaccine formulations comprised of these materials including their physiochemical properties, fabrication, characterization, and biologic responses in vivo are highlighted. The review is concluded with future perspectives for nano/microparticles as carrier systems and other considerations within the universal influenza vaccine delivery landscape. [Figure: see text] Springer International Publishing 2022-01-07 /pmc/articles/PMC8741137/ /pubmed/34997352 http://dx.doi.org/10.1208/s12248-021-00676-9 Text en © The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Article Hendy, Dylan A. Amouzougan, Eva A. Young, Isabella C. Bachelder, Eric M. Ainslie, Kristy M. Nano/microparticle Formulations for Universal Influenza Vaccines |
title | Nano/microparticle Formulations for Universal Influenza Vaccines |
title_full | Nano/microparticle Formulations for Universal Influenza Vaccines |
title_fullStr | Nano/microparticle Formulations for Universal Influenza Vaccines |
title_full_unstemmed | Nano/microparticle Formulations for Universal Influenza Vaccines |
title_short | Nano/microparticle Formulations for Universal Influenza Vaccines |
title_sort | nano/microparticle formulations for universal influenza vaccines |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741137/ https://www.ncbi.nlm.nih.gov/pubmed/34997352 http://dx.doi.org/10.1208/s12248-021-00676-9 |
work_keys_str_mv | AT hendydylana nanomicroparticleformulationsforuniversalinfluenzavaccines AT amouzouganevaa nanomicroparticleformulationsforuniversalinfluenzavaccines AT youngisabellac nanomicroparticleformulationsforuniversalinfluenzavaccines AT bachelderericm nanomicroparticleformulationsforuniversalinfluenzavaccines AT ainsliekristym nanomicroparticleformulationsforuniversalinfluenzavaccines |